Race Investor Presentation
Released
Released
Announcement PDF
March
2025
AT THE
HEART OF
CANCER CARE
Pete Smith PhD, Exec Chair
Daniel Tillett PhD, CEO and Managing Director
INVESTOR PRESENTATION
0
1
ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
T H E
H E A R T
O F
Race is approaching several critical data/value inflection points
A T
Why invest in Race Oncology now?
C A N C E R
Improved drug - RC220
Patient focused
Data imminent
Many value drivers
Investor focused
Used in numerous clinical
trials. Established safety
and anti-cancer activity
Open label RC220 clinical
trial starts this quarter
Reformulated for easier
administration. 20 years of
IP protection
Significant news flow
throughout 2025. Positive
sentiment in sector
Increasing focus on the
health of cancer survivors
C A R E
Validated drug
Ethos, communication
and funding strategies
2
A T
T H E
H E A R T
O F
C A N C E R
C A R E
We are focused on
protecting patients,
while optimising their
cancer treatment
3
3
A T
Original bisantrene
T H E
H E A R T
A highly effective, but commercially unviable anticancer drug
O F
C A N C E R
Approved in France in 1988
C A R E
Excellent patient outcomes. Complete response rates above 40%
as a salvage drug in leukaemia
In a large Phase 3 breast cancer trial bisantrene equalled
standard of care, but with less heart damage and hair loss
Lederle (Pfizer) ended commercial development after more than 50
trials due to the difficulty administering the drug to patients
4
A T
RC220 – our new, improved bisantrene
T H E
H E A R T
O F
Race has…
C A N C E R
C A R E
• Created RC220, a new formulation of bisantrene which
is more soluble and can be delivered peripherally 1
• RC220 preserves the PK/PD properties of the earlier
clinically validated formulations of bisantrene
• Created new intellectual property (patents) with a long
lifespan (20 years)
• Leveraged new science to understand the anti-cancer and
cardioprotective mechanism of action of bisantrene 2
• Built on the >1,500 patients’ worth of clinical data across
a broad range of cancer indications and generated new
Phase 2 clinical data
1. ASX Announcement: 9 November 2023 | 2. ASX Announcement: 21 September 2023
RC220 is a clinically &
commercially attractive
formulation with long IP life
5
A T
RC220 + doxorubicin = improved activity
T H E
H E A R T
Lymphoid
1. ASX Announcement: 21 September 2023 | 2. 143 cancer cell lines screened.
C A R E
85%
Cancers where bisantrene improved doxorubicin
Lung
of all cancers2
C A N C E R
RC220 improves doxorubicin anti-cancer activity in:
O F
RC220 shows potent cell-killing activity against a diverse range of human cancers when used alone and in
combination with doxorubicin, the most frequently used anthracycline1
Prostate
Bowel
Myeloid
Breast
Sarcoma
CNS / Brain
Ovarian
Uterus
Skin
Pancreas
Upper GI tract
6
H E A R T
O F
35%
Good Responders
30%
C A N C E R
25%
C A R E
Objective Response Rate (%)
T H E
40%
20%
15%
Poor Responders
10%
5%
0%
A T
Doxorubicin single agent efficacy in the advanced
or metastatic stage of common solid cancers1
Breast
SCLC
Ovary
Bladder
Liver
Endometrial
Upper GI
Thyroid
NSCLC
Prostate
Kidney
Lower GI
Melanoma
(n = 1741)
(n = 53)
(n = 193)
(n = 412)
(n = 119)
(n = 451)
(n = 134)
(n = 180)
(n = 184)
(n = 155)
(n = 133)
(n = 77)
(n = 73)
Doxorubicin can achieve objective response rates of 15% to 40%
in advanced/metastatic cancers across many common cancer types2
1. Common solid cancers evaluated included the ten most prevalent solid tumour types based on the number of new cases diagnosed annually in the United States, China, and Australia.
2. Data on file from 73 studies published between 1969 and 2008. Cancer types with treatment data from <50 evaluable patients were excluded (pancreatic and cervical cancer).
GI, gastrointestinal. Upper GI includes esophageal and stomach cancers; Lower GI includes colon and rectal cancers. NSCLC, non-small cell lung cancer. SCLC, small cell lung cancer.
A T
RC220 = protecting the heart
T H E
RC220 + doxorubicin
O F
Doxorubicin
H E A R T
No treatment (control)
C A N C E R
C A R E
No Fibrosis (scarring)
Extensive Fibrosis
Minimal Fibrosis
Animal studies demonstrated cardioprotection by RC220 including increased cardiac
function and reduced fibrosis when compared to doxorubicin alone1
1. ASX Announcement: 30 June 2022
8
Why do we need to
protect patients from
their cancer treatment?
99
A T
Doxorubicin damages the cardiovascular system
T H E
H E A R T
VO2peak is the ‘gold standard’ measure of cardiovascular function
O F
C A N C E R
Prevents patients
performing basic daily
living activities
Low VO2peak
associated with a 7-9fold increased risk of
heart failure 1
C A R E
A VO2peak below
18mL/kg/min leaves a
patient ‘functionally
disabled’
Doxorubicin reduces VO2peak in patients by 8-11% 1
- Equivalent to 8-11 years of ageing
VO2peak will be used in up coming clinical trials to demonstrate
clinical benefit of RC220
1. Howden, E. J. et al. Traditional markers of cardiac toxicity fail to detect marked reductions in cardiorespiratory fitness among cancer patients undergoing anti-cancer treatment. Eur. Hear.
J. - Cardiovasc. Imaging 22, 451–458 (2021).
10
A T
Cancer survivorship – life after treatment
T H E
Pressing need for better approaches
Clinician
interest
Race.
Heart
damage
+ other
effects
Better
diagnosis
+ therapy
C A R E
A single dose of chemotherapy can cause
cardiotoxicity 3 and muscle atrophy 4
C A N C E R
18m cancer survivors in the US 1 with a 37%
increased risk of cardiovascular disease 2
O F
Ageing
H E A R T
Driving factors
and tailwinds
for RC220
Cardiovascular damage is permanent 4
New specialties such as cardio-oncology
are focused on reducing the damage
caused by cancer treatments
1. www.cancer.gov
2. Florido R, et al. J Am Coll Cardiol, 2022
3. Dillon HJ, et al. J Am Coll Cardiol, 2024
4. Mallard J, et al. J Cachexia Sarcopenia Muscle, 2024
11
A T
Chemotherapy needs improvement
T H E
H E A R T
O F
Issue – patients not given full
effective dose, and heart damage
with serious long-term health
consequences remains
Opportunity – if the cardiovascular
toxicity could be reduced, more
patients could be treated and
more effective regimens delivered
C A R E
Current solution – exclude use in
high-risk patients and limit
dosing of the drugs
C A N C E R
Doxorubicin is the most widely used
chemotherapy. It is highly effective,
but can cause permanent damage
to the cardiovascular system
“Cardiotoxicity, which includes heart failure, is
one of the main side effects limiting the use of
these effective therapies.”
Professor Aaron Sverdlov, University of Newcastle
12
Clinical programs
13
A T
Clinical pipeline
T H E
Phase
1
Acute Myeloid
Leukaemia
RC220
Cardioprotection + m6A
RNA + anti-cancer
efficacy - solid tumours3
Race Oncology
Phase 1a/b
Q1
CY25
RC220
Acute Myeloid
Leukaemia4
Investigator
sponsored
Phase 1/2
H1
CY25
m6A RNA
molecule
development
Next generation
bisantrene
Race Oncology
Preclinical
Results & milestones
Impressive 40% clinical
response rate in Phase 2
AML trial completed in June
2020
Phase 2
Successfully concluded with
40% response rate in July
20242. Publication of clinical
data anticipated
Phase 2
2026
1. https://announcements.raceoncology.com/announcements/3617104 | 2. https://announcements.raceoncology.com/announcements/6454612 |
3. https://announcements.raceoncology.com/announcements/6429352 | 4. https://announcements.raceoncology.com/announcements/5437127
C A R E
Bisantrene
(RC110)
Chaim Sheba
Medical Centre,
Israel
Phase
3
C A N C E R
Acute Myeloid
Leukaemia
Chaim Sheba
Medical Centre,
Israel
Phase
2
O F
Sponsor
Bisantrene
(RC110)
Discovery
IND
enabling
Indication
H E A R T
Asset
Ethics / governance
approvals
First patient dosed
Confirmation of trial
Preliminary results
14
A T
Recent clinical trial results
T H E
H E A R T
C A R E
• Data from these two recent clinical
studies is further evidence that RC220 is
an effective anti-cancer therapy
• Patients treated in these studies were
very unwell, and some had failed up to 9
prior lines of other therapies
• Results from these studies were
compelling and beyond expectations of
the clinicians
C A N C E R
• Sheba 2 (2024) – 40% response
rate in 15 heavily pre-treated
AML salvage patients with
combination treatment 2
O F
• Sheba 1 (2020) – 40% response
rate in 10 AML salvage patients
using bisantrene as a single
agent – 4/4 clinical response in
EMD AML 1
1. ASX Announcement: 16 June 2020 | 2. ASX Announcement 6 November 2023
15
A T
RC220 Phase 1 open label cardioprotection trial
T H E
Combination cycle 1
RC220 IV + Dox IV
Combination cycles 2-6
RC220 IV + Dox IV
C A R E
Start: First patient
expected Q1 CY2025
Safety lead in cycle:
RC220 IV 21d cycle
C A N C E R
Exploratory endpoints:
Standard & advanced
cardiac markers including
VO2peak, m6A levels &
anticancer efficacy
Part 1: Advanced solid tumour patients with potential to
benefit from doxorubicin therapy
O F
Primary endpoints: Safety
& optimal Phase 2 dose
determination
H E A R T
Up to 53 patients across
the two stages
Part 2: Anthracycline naïve solid tumour patients with
potential to benefit from doxorubicin therapy
Combination cycle 1
RC220 IV + Dox IV
Combination cycle 2- 6
RC220 IV + Dox IV
16
A T
T H E
Planned clinical trial geographies
H E A R T
O F
C A R E
Hong Kong: 2 Sites
C A N C E R
Australia: 4 Sites
South Korea: 4 Sites
17
A T
T H E
H E A R T
O F
C A N C E R
C A R E
Market
opportunity
18
A T
RC220 market opportunity
T H E
cardioprotection + anti-cancer2
US$1.5b
US$7b
C A N C E R
doxorubicin - 20231
O F
Annual revenue RC220
H E A R T
Annual revenue generic
C A R E
Note: Forecasted revenue
reflect a 50% reduction to the
physician-stated adoption rate
USD$100 base price/cycle for 4 cycles
1. https://www.theinsightpartners.com/reports/doxorubicin-market
2. Triangle Insights (ASX Announcement: 14 April 2023)
USD$15,000 base price/cycle for 4 cycles with a 3% yearly
net price increase after launch
19
A T
Use of doxorubicin & other anthracyclines is growing1, 2, 3
T H E
H E A R T
Annual doses of doxorubicin and other anthracyclines (m)1
O F
22.98
18.97
15.66
2023
16.69
2024
20.22
17.79
2025
China & Japan
2026
EU-5
Russia
2027
United States
2028
India
2029
Australia
2030
1. IQIVIA MIDAS AUDITED US VOLUME Anthracycline
Data, Triangle Insights (ASX Announcement,
slide 16: 14 April 2023)
2. Daunorubicin, doxorubicin, liposomal doxorubicin
(Doxil), epirubicin, idarubicin, mitoxantrone, and
valrubicin
3. Triangle Insights (ASX Announcement: 14 April
2023)
C A R E
21.55
According to Data Bridge Market
Research, global anthracycline usage is
expected to increase by a CAGR
of 6.60% between 2023 and 2030
C A N C E R
24.49
20
Prof Tom Neilan
Cardio-Oncologist
Harvard Medical
School, Boston, MA,
USA
Prof Josh Mitchell
Cardio-Oncologist
Washington University,
St Louis, MO, USA
A/Prof Erin Howden
Head of the Cardiometabolic
Health and Exercise Physiology Lab
Baker Heart and Diabetes Institute,
Melbourne, Australia
C A R E
I am passionate about
reducing the burden of
cardiovascular disease for
cancer patients
C A N C E R
Prof Aaron Sverdlov
Cardiologist
University of Newcastle,
NSW, Australia
Toxicity is highest in the
first year, but risk of
heart failure remains
increased for the rest of
their life
O F
Dr Chau Dang
Medical Oncologist
(Breast Cancer)
Memorial Sloan
Kettering Cancer Center
NY, USA
It depends how carefully
you look, but at least
30% of patients who are
treated with anthracyclines
have evidence of
cardiac toxicity
H E A R T
9-14% of patients on
anthracycline regimens
develop symptomatic
cardiac dysfunction
T H E
Scope for new
cardioprotective therapy in
addition to doxorubicin if it
increases anticancer
efficacy
A T
Views of key opinion leaders
21
A T
Corporate snapshot
T H E
H E A R T
Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the
heart of cancer care. We are well funded to support our current programs.
O F
RAC
Share price
$1.25 1
Market capitalisation
$217.15m 1
Cash at bank
$18.78m 2
Debt
Nil
Enterprise value
$198.37m 1
Shares on issue
173,721,858 1
Options on issue
33,136,559 1
1. As at 14 March 2025
2. As at 31 December 2024
C A R E
ASX code
C A N C E R
Race 12-month trading history
Key Data
Current Funding
On 22 November 2023, Race issued a 1 for 20 bonus and piggyback option series to
existing shareholders. The conversion of bonus options ($0.75) raised $5m and the
19.9m piggyback options ($1.25) could raise an additional $25m before expiry 29 May
2026
22
A T
Race Oncology Board
T H E
H E A R T
O F
C A N C E R
C A R E
• Former CSO and Executive Director
of Race Oncology (2019-2023)
• Responsible for development of
RC220 & cardioprotection discoveries
• >25 years of biotech management
experience (Nucleics)
• Largest Race Oncology shareholder
(>10%)
•
•
•
>30 years' experience in healthcare
with focus on therapeutics /
oncology
Founder and CEO of Amala
Therapeutics
Former top-rated pharma analyst
with UBS and HSBC
Dr Megan Baldwin PhD
Non-Executive Director
Dr Serge Scrofani PhD MBA
Non-Executive Director
Dr Peter Smith PhD
Executive Chair
Dr Daniel Tillett PhD
Managing Director / CEO
•
•
•
>28 years’ experience in healthcare
including research, strategy,
licensing, M&A
Principal at Poplar Advisory Pty Ltd,
Executive Director at FinCap Pty
Ltd, Non-Executive Director at
Burnet Institute & The Centre for
Eye Research Australia
Former Vice President of Strategy &
Corporate Development at CSL
•
•
•
•
>25 years' experience in therapeutic
drug development in oncology and
ophthalmology
Experienced CEO and currently
Founder and Chief Innovation Officer
of Opthea Ltd (Nasdaq:ASX:OPT)
Non-Executive Director on public and
private company boards and
Ausbiotech
Previously at Genentech in R&D and
commercial roles
23
First patient treated in Phase 1/2 AML study
C A R E
Updates on clinical trial progress
C A N C E R
Publication of results from Sheba Phase 2 clinical study in AML
O F
Additional preclinical results on bisantrene mechanism of action
H E A R T
File Investigational New Drug (IND) application with US Food
and Drug Administration for RC220
T H E
For CY25
A T
Upcoming milestones
First patient treated in Phase 1a/1b RC220 solid tumours (all comers) trial
Governance approval for Phase 1a/1b trial in solid tumours
Ethics approval for Phase 1a/1b trial in solid tumours
Contract executed with CRO to support Phase 1a/1b RC220 trial in sold tumours
The RC220 trial is open label so regular news is expected
1. All dates are estimates and subject to change
24
A T
Typical risks in drug development (illustrative)
T H E
PRECLINICAL
Lack of preclinical
efficacy or
toxicity
Toxic in man
Lack of efficacy
Preclinical efficacy
and toxicity known
for combination
Known toxicity as
single agent and in
other combinations
Efficacy established for
single agent and other
combinations
NDA
Lack of efficacy, emerging
toxicity
Efficacy and safety established
for single agent
MKT
Data
insufficient
for approval
Race has a distinct
advantage with RC220
due to the prior clinical
success of bisantrene
C A R E
Chance of a drug making it to market
PHASE III
C A N C E R
Known molecule
PHASE II
O F
Key risks
Failure to find
suitable molecule
PHASE I
H E A R T
DISCOVERY
96%
80%
50%
25%
1%
1
10%
3%
2
3
4
5
6
7
8
9
10
11
12
13
14
Years
25
H E A R T
O F
C A N C E R
C A R E
Solves a real & significant health problem
– permanent damage caused by
chemotherapy, increasing due to longevity
and increasing population
T H E
RC220 – derisked & clinically proven anticancer drug offering ~80% chance of success
- not ~3% common in oncology
A T
Key highlights of Race Oncology
RC220 builds on a major existing market of
20m anthracycline doses/year, potential
sales >US$5B/year
Low-cost development with an opportunity
for a rapid pathway to market via the FDA
accelerated approval process from Phase 2
Management invested with proven technical,
deal & ASX track record
26
Questions
Race Oncology
A T
T H E
H E A R T
O F
C A N C E R
C A R E
27
NOT FINANCIAL PRODUCT ADVICE
C A R E
This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any securities described in this presentation have not been, and will not be, registered under the US Securities Act of 1933, as
amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the Securities Act and
applicable US state securities laws. This presentation may not be released to US wire services or distributed in the United States. The distribution of this presentation in other jurisdictions outside Australia may also be restricted by law and any such
restrictions should be observed.
C A N C E R
Statements in this presentation are made only as of the date of this presentation unless otherwise stated and the information in this presentation remains subject to change without notice. No representation or warranty, express or implied, is made as
to the fairness, accuracy or completeness of the information, opinions and conclusions contained in this presentation or any other information the Company or any other person otherwise provides to you.
O F
This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Corporations Act 2001 (Cth) (Corporations Act). It has not been lodged with the Australian Securities and Investments Commission, or
otherwise.
H E A R T
THIS IS NOT A PROSPECTUS
T H E
The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company).
A T
Important Notice and Disclaimer
No attempt has been made to independently verify the information contained in this presentation. The information in this presentation is of a general nature and does not constitute financial product advice, investment advice or any recommendation.
Nothing in this presentation constitutes legal, financial, tax or other advice. The information in this presentation does not take into account your particular investment objectives, financial situation or needs, or those of any other person. You should
make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own investigations and analysis of the financial condition, assets and liabilities, financial position and
performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.
THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR ADVERTISEMENT
This presentation does not constitute an invitation, offer or recommendation to apply for or purchase Shares and does not contain any application form for Shares. This presentation does not constitute an advertisement for an offer or proposed offer of
Shares.
NO LIABILITY
The Company has prepared this presentation based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in this presentation. No representation or warranty, express or implied, is
made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of the Company or its subsidiaries or affiliates or the directors,
employees, agents, representatives or advisers of any such party, nor any other person accepts any liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including without limitation, any
liability arising from fault or negligence on the part of the Company or its subsidiaries or affiliates or the directors, employees, agents, representatives or advisers of any such party.
FORWARD-LOOKING STATEMENTS
This presentation may contain forward-looking statements that are subject to risk factors associated with an oncology company. Forward looking statements can be identified by the use of forward-looking terminology, including, without limitation, the
terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “goals”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or
comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and
depend on circumstances that may or may not occur in the future and may be beyond the Company’s ability to control or predict which may cause the actual results or performance of the Company to be materially different from the results or
performance expressed or implied by such forward-looking statements. Forward looking statements are based on assumptions and are not guarantees or predictions of future performance. No representation is made that any of these statements or
projections will come to pass or that any forecast result will be achieved, nor as to their accuracy, completeness or correctness. Similarly, no representation is given that the assumptions upon which forward looking statements may be based are
reasonable.
28
Contact
PETE SMITH
Executive Chair
ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Investor & Media Relations
+61 2 8051 3043
+61 411 117 774
peter.smith@raceoncology.com
jane.lowe@irdepartment.com.au
www.raceoncology.com
Authorised for release by the Board
JANE LOWE
Share your feedback
Discover